Evaluating plaque progression in coronary artery disease using advanced imaging techniques
Official title: Evaluation of Atherosclerotic Plaque Progression by Coronary Computed Tomography Angiography and Intracoronary Imaging Techniques in Patients With Coronary Artery Disease
Run by Ruijin Hospital · NCT06794684 · Data updated 2026-11-12
This study is testing how advanced imaging can help us understand the growth of plaque in the arteries of people with coronary artery disease over five years and how different factors and treatments affect their heart health.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 50000 (estimated) |
| Sponsor | Ruijin Hospital Academic / other |
| Locations | 2 sites (Shanghai and 1 other locations) |
| Status | Recruiting |
| Started | January 1, 2016 |
| Main results expected | May 31, 2027 |
| Study ends | May 31, 2030 |
| Registry record updated | January 27, 2025 |
| Trial ID | NCT06794684 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 and older with clinically significant angina or suspected CAD who have visible plaque on coronary CTA.
✕Probably not a fit
Patients with severe renal impairment, recent coronary interventions, or significant comorbidities such as malignancies or advanced heart failure may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational cohort study involves patients with coronary artery disease (CAD) who will be followed for up to 5 years. Participants will undergo repeat coronary CT angiography (CTA) after 2 years, and those referred for invasive coronary angiography will receive additional intracoronary imaging techniques. The study aims to analyze the morphological and functional characteristics of atherosclerotic plaques, their progression, and the impact of various cardiometabolic factors and treatments on major adverse cardiovascular events (MACEs). Blood samples will also be collected for further analysis.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and management of coronary artery disease, potentially reducing the risk of major cardiovascular events.
How similar studies have gone: Other studies utilizing advanced imaging techniques for plaque analysis have shown promise, indicating that this approach may yield valuable insights into CAD management.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years * Clinically significant angina pectoris, or suspected CAD * Receive coronary CTA scan, with a visible plaque (defined as ≥25% diameter stenosis) in major coronary arteries. Exclusion Criteria: * Unsuitable for coronary CTA (such as severe renal impairment, uncontrolled thyroid condition, allergic to iodine, etc.) * Receive percutaneous coronary intervention (PCI) within 6 months * Prior history of myocardial infarction or heart failure * Prior history of percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) * Abnormal liver function (serum alanine aminotransferase \[ALT\] level exceeding 3 times the upper limit of normal) or abnormal kidney function (eGFR ≤30 ml/min) * Familial hypercholesterolemia * Estimated survival ≤ 1 year * Malignant tumor * Pregnant or lactation, or have the intention to give birth within one year * Poor coordinance, unable to follow-up
Where it's running
-
CAAC East China Aviation Personnel Medical Appraisal Center, Civil Aviation Shanghai Hospital
Shanghai, China Recruiting -
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, China Recruiting
Study contacts
- Principal investigator: Ruiyan Zhang, M.D., Ph.D. — Ruijin Hospital
- Study coordinator: Xiaoqun Wang
- Email: wangxq@shsmu.edu.cn
- Phone: +86 21 64370045 671605
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Red grape juice and metabolism in men with coronary disease
Researchers will test whether daily red grape juice changes the blood metabolite profile in men with chronic coronary artery disease.
-
Edoxaban vs. Apixaban in AF with CAD: Net Benefit
This trial tests whether edoxaban-based therapy provides a similar or better overall benefit than apixaban-based therapy for stroke prevention and major bleeding in adults with atrial fibrillation and coronary artery disease.
-
Revascularization of Calcified Coronary Arteries
This study tests whether measuring blood flow and pressure before and after ballooning or stenting of calcified coronary arteries can help predict how well the procedure will work for adults with heart disease.
-
OPN Balloon Use for Recanalization of Calcified Coronary Lesions
This registry tests how the SIS-OPN balloon is used in real-world patients with calcified coronary disease who have undergone PCI in North America.
-
Pulse IVL to open calcified coronary vessels in CAD
A small, early feasibility study tests the Pulse Intravascular Lithotripsy system in adults with coronary artery disease to see if it can safely open calcified arteries and improve vessel compliance.
-
Crystalline sirolimus-coated balloon for treating coronary artery disease
This tests whether a crystalline sirolimus-coated balloon is safe and effective for adults having percutaneous coronary intervention for coronary artery blockages or in-stent restenosis.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.